|
Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM). |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; NeraCare GmbH; Novartis; Philogen; Pierre Fabre; Roche; Sanofi |
Research Funding - Bristol-Myers Squibb (Inst); NeraCare GmbH (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; NeraCare GmbH; Novartis; Philogen; Roche; Sanofi |
|
|
Research Funding - Novartis (Inst); Pierre Fabre (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Research Funding - Novartis (Inst); Pierre Fabre (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Consulting or Advisory Role - NeraCare GmbH |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Roche Pharma AG |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche Pharma AG |
|
|
No Relationships to Disclose |